Adintrevimab Biosimilar – Anti-Spike RBD mAb – Research Grade

Introduction to Adintrevimab Biosimilar

Adintrevimab Biosimilar, also known as Anti-Spike RBD mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Adalimumab. It specifically targets the receptor binding domain (RBD) of the spike protein on the surface of the SARS-CoV-2 virus, making it a promising treatment option for COVID-19. In this article, we will explore the structure, activity, and potential applications of Adintrevimab Biosimilar in more detail.

Structure of Adintrevimab Biosimilar

Adintrevimab Biosimilar is a recombinant humanized monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It belongs to the immunoglobulin G (IgG) class of antibodies and has a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, each containing variable and constant regions. The variable regions are responsible for binding to the RBD of the SARS-CoV-2 spike protein, while the constant regions determine the antibody’s effector functions.

The structure of Adintrevimab Biosimilar is highly similar to that of Adalimumab, with only minor differences in the amino acid sequence. This is because Adintrevimab Biosimilar has been designed to be a biosimilar, meaning it has a highly similar structure and function to the original therapeutic antibody.

Activity of Adintrevimab Biosimilar

Adintrevimab Biosimilar has a high affinity for the RBD of the SARS-CoV-2 spike protein, allowing it to bind to and neutralize the virus. This prevents the virus from entering and infecting host cells, thereby reducing the severity of COVID-19 symptoms. Additionally, the antibody can also activate the immune system to produce an immune response against the virus.

Studies have shown that Adintrevimab Biosimilar is effective in neutralizing a variety of SARS-CoV-2 variants, including the highly transmissible Delta variant. This makes it a promising treatment option for COVID-19, especially in areas where these variants are prevalent.

Applications of Adintrevimab Biosimilar

Adintrevimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of COVID-19. It is being developed as a research-grade antibody, meaning it is intended for use in laboratory research and not for human therapeutic purposes.

Aside from its potential use as a treatment for COVID-19, Adintrevimab Biosimilar can also be used in research to study the structure and function of the SARS-CoV-2 spike protein. Its high affinity for the RBD makes it a valuable tool in understanding the virus and developing potential treatments and vaccines.

Conclusion

In conclusion, Adintrevimab Biosimilar is a promising monoclonal antibody that specifically targets the RBD of the SARS-CoV-2 spike protein. Its highly similar structure to the therapeutic antibody Adalimumab, along with its ability to neutralize a variety of SARS-CoV-2 variants, makes it a potential treatment option for COVID-19. As a research-grade antibody, it also has important applications in studying the virus and developing treatments and vaccines. Further clinical trials will determine the full potential of Adintrevimab Biosimilar in the fight against COVID-19.